Home - Products - GPCR/G Protein - Dopamine Receptor - 4,7-DIHYDROXYCOUMARIN

4,7-DIHYDROXYCOUMARIN

CAS No. 1983-81-9

4,7-DIHYDROXYCOUMARIN( —— )

Catalog No. M18195 CAS No. 1983-81-9

4, 7-DIHYDROXYCOUMARIN is a bioactive natural compound.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	28	In Stock
50MG	33	In Stock
100MG	49	In Stock
200MG	Get Quote	In Stock
500MG	119	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

4,7-DIHYDROXYCOUMARIN
Note

Research use only, not for human use.
Brief Description

4, 7-DIHYDROXYCOUMARIN is a bioactive natural compound.
Description

4, 7-DIHYDROXYCOUMARIN is a bioactive natural compound.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

GPCR/G Protein
Target

Dopamine Receptor
Recptor

others
Research Area

——
Indication

——

Chemical Information

CAS Number

1983-81-9
Formula Weight

178.14
Molecular Formula

C9H6O4
Purity

>98% (HPLC)
Solubility

——
SMILES

Oc1ccc2c(c1)oc(=O)cc2O
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

GSK598809

GSK598809 (GSK-598809) is a potent, selective, CNS penetrant and orally bioavailable dopamine D3 receptor antagonist with pKi of 8.9; displays >100-fold selectivity over D2 and H1 receptors.
Chlorpromazine

Chlorpromazine (CPZ) is a phenothiazine acting as dopamine antagonist.Chlorpromazine is a low-potency typical antipsychotic agent for the treatment of psychotic disorders such as schizophrenia.Chlorpromazine (CPZ) is a phenothiazine acting as dopamine antagonist.?
ONC206

ONC206 is an analogue of TRAIL inducer ONC201 and is a selective antagonist of the D2-like dopamine receptors (DRD2/3/4) at nanomolar concentrations. ONC206 also has broad-spectrum anti-tumor activity. ONC206 (Oncoceutics) is an imipiridone with nanomolar potency and analogue of ONC201, a selective dopamine receptor D2 (DRD2) antagonist currently being investigated in phase II clinical trials for serous endometrial cancer (SEC).??

Sign In Join Free